NCT04982068进行中（未招募）1 期
A Randomized, Double-blinded, Placebo-controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability, and Preliminary Immunogenicity of the Recombinant SARS-CoV-2 Vaccine (CHO Cell) in Healthy Adults Aged 18 Years and Above
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 72
- 试验地点
- 1
- 主要终点
- Incidence of solicited adverse events (AEs) after vaccination
研究概览
简要总结
The purpose of this double-blind, randomized, controlled study is to assess safety, reactogenicity, and preliminary immunogenicity of 202-CoV at multiple dose levels, administered as 2 injections (i.m) at 28 days apart in adult subjects 18 years of age and above.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy individuals aged 18-59 years as well as 60 years and above who can provide legal identification (males and females are both required).
- •Willing to participate in the study with informed consent prior to screening
- •Negative in SARS-CoV-2 IgG and IgM test at screening.
- •Women of childbearing potential must be using effective method of birth control for 14 days prior to the enrollment of the study vaccine/placebo and must agree to continue such precautions during the study until 30 days after the second dose of the study vaccine/placebo.
- •Male subjects must agree to employ acceptable contraception from the day of first dose of the study vaccine/placebo until 30 days after the second dose of the study vaccine/placebo.
排除标准
- •Confirmed or asymptomatic COVID-19 cases or SARS-CoV-2 infection(had positive in SARS-CoV-2 nucleic acid test or serological test).
- •Had a history of traveling or residence in domestic area of high and moderate pandemic risk, overseas or epidemic areas, or had a history of contact with confirmed, asymptomatic or suspected COVID-19 cases within the past 14 days;
- •History of SARS;
- •Received SARS-CoV-2 vaccines for emergency use or approved SARS-CoV-2 vaccines;
- •Individuals involving a clinical study within 6 months prior to the screening visit; or planning to participate in another clinical study during study period.
- •Clinical laboratory abnormalities and with clinical significance judged by investigator
- •Individual's systolic blood pressure ≥ 150mmHg and/or diastolic blood pressure ≥ 100mmHg at screening visit
- •Axillary temperature >=37.3℃ prior to vaccination
- •Individuals in other acute diseases, or in the acute phase of chronic diseases within 3 days prior to the signing of the informed consent form.
- •Received immunoglobulin and/or blood product 3 months prior to the first vaccination.
- •Presence of uncontrolled chronic pulmonary, cardiovascular, renal, hepatic, neurologic, hematologic or metabolic (including diabetes mellitus) disorders, which would include the potential subject in a high-risk category for SARS-CoV-2 infection and/or its complications as judged by the investigator..
- •Individuals with a history of severe allergic reaction (throat swelling, difficult in breath, dyspnea, or shock).
- •Individuals who have a history of severe adverse reaction associated with a vaccine or severe allergic reaction [e.g., anaphylaxis to any component of the study vaccines (S protein, Aluminum hydroxide, CpG adjuvant).
- •Any autoimmune or immunodeficiency disease/condition [e.g. human immunodeficiency virus (HIV) infection, Systemic lupus erythematosus (SLE)]
- •Received immunoglobulin, blood-derived products within 3 months prior to the first study vaccination.
- •Abnormal coagulation function (such as coagulation factor deficiency, coagulation disease, platelet abnormality) obvious bruises or coagulopathy.
- •Pregnant women or breastfeeding women.
- •According to the judgment of the investigator, subject has or had any other symptoms, medical history and other factors that are not suitable for participating in this clinical trial.
结局指标
主要结局
Incidence of solicited adverse events (AEs) after vaccination
时间窗: 7 days after the first or second vaccination
Percentage of participants with solicited AEs (local, systemic) for 7 days following each primary vaccination (Days 0, 28) by intensity, relevance.
Incidence of unsolicited AEs after vaccination
时间窗: Frame: Day 0 to Day 56
Percentage of participants with unsolicited AEs for 28 days following each vaccination
次要结局
- Proportion of subjects with abnormal markers of hematology, biochemistry, urinalysis and coagulation parameters(Day 4 after first or second vaccination)
- Geometric mean titer (GMT) of SARS-CoV-2 neutralising antibodies(Day0, Day28, Day42 and Day56)
- Seroconversion rate (SCR) of SARS-CoV-2 neutralising antibodies(Day0, Day28, Day42 and Day56)
- Geometric mean titer (GMT) of Serum IgG Antibody Levels(Day0, Day28, Day42 and Day56)
- Seroconversion rate (SCR) of Serum IgG Antibody Levels(Day0, Day28, Day42 and Day56)
- Incidence of serious AEs (SAEs) and adverse events of special interest (AESIs)(Day 0 to Month 13)
研究者
研究点 (1)
Loading locations...
相似试验
进行中（未招募）
1 期
Safety and Immunogenicity of Recombinant SARS-CoV-2 Spike Protein Vaccine (CHO Cell) for the Prevention of COVID-19COVID-19NCT05313022Shanghai Zerun Biotechnology Co.,Ltd84
已完成
2 期
A Efficacy Study of PRX-00023 in Patients With Major Depressive DisorderMajor Depressive Disorder (MDD)NCT00448292Epix Pharmaceuticals, Inc.330
已完成
3 期
Safety and Therapeutic Effects of Sapropterin Dihydrochloride on Neuropsychiatric Symptoms in Phenylketonuria (PKU) PatientsPhenylketonuriaNCT01114737BioMarin Pharmaceutical206
已完成
2 期
Evaluation of Safety and Efficacy of Intravenous Sulbactam-ETX2514 in the Treatment of Hospitalized Adults With Complicated Urinary Tract InfectionsAcute PyelonephritisComplicated Urinary Tract InfectionNCT03445195Entasis Therapeutics80
已完成
2 期
Safety and Efficacy Study of LUM001 in the Treatment of Cholestatic Liver Disease in Patients With Alagille SyndromeAlagille SyndromeNCT01903460Mirum Pharmaceuticals, Inc.20